Research Topics
| C StrangeSummaryAffiliation: Medical University of South Carolina Country: USA Publications
| Collaborators
|
Detail Information
Publications
Association of IREB2 and CHRNA3 polymorphisms with airflow obstruction in severe alpha-1 antitrypsin deficiencyWoo Jin Kim
Channing Laboratory and the Division of Pulmonary and Critical Care Medicine, Brigham and Women s Hospital, and Harvard Medical School, Boston, MA, USA
Respir Res 13:16. 2012..We investigated whether SNPs in the chromosome 15q region would be modifiers for lung function and COPD in AAT deficiency...- Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha₁-antitrypsin deficiency: a randomized studyJames M Stocks
Department of Medicine, University of Texas Health Science Center at Tyler, 75708 3154, USA
BMC Clin Pharmacol 10:13. 2010..The pharmacokinetic comparability of Prolastin-C to Prolastin was assessed in subjects with AAT deficiency... - Design of the Endobronchial Valve for Emphysema Palliation Trial (VENT): a non-surgical method of lung volume reductionCharlie Strange
Division of Pulmonary and Critical Care Medicine, Medical University of South Carolina, Charleston, SC, USA
BMC Pulm Med 7:10. 2007.... - Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung diseaseCharlie Strange
Division of Pulmonary and Critical Care Medicine, MUSC, 96 Jonathan Lucas Street, 812 CSB, Charleston, SC 29425, USA
Am J Respir Crit Care Med 177:91-8. 2008..The presence of inflammatory cells on bronchoalveolar lavage is often used to predict disease activity and the need for therapy in systemic sclerosis-associated interstitial lung disease... 
Infection in the intensive care unit: a clinician's view of the role of imagingCharlie Strange
Medical University of South Carolina, 96 Jonathan Lucas Street, Charleston, SC 29425, USA
Semin Roentgenol 42:7-10. 2007- Genetic testing of minors for alpha1-antitrypsin deficiencyCharlie Strange
Division of Pulmonary and Critical Care Medicine, Medical University of South Carolina, Charleston 29425, USA
Arch Pediatr Adolesc Med 160:531-4. 2006..Alpha(1)-antitrypsin deficiency (AATD) is a genetic disorder primarily affecting the lungs and liver of affected individuals, causing severe panlobular emphysema and cirrhosis... - Results of a survey of patients with alpha-1 antitrypsin deficiencyCharlie Strange
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Medical University of South Carolina, Charleston, 29425, USA
Respiration 73:185-90. 2006..alpha(1)-Antitrypsin deficiency (AATD) is an uncommon genetic disease which occurs in 1-2.5% of Americans with chronic obstructive pulmonary disease (COPD). Little is known about current demographics of AATD... - Pulmonary hypertension in interstitial lung diseaseCharlie Strange
Division of Pulmonary and Critical Care Medicine, Allergy and Clinical Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina 29425, USA
Curr Opin Pulm Med 11:452-5. 2005..Antifibrotic therapies for interstitial lung disease remain unproved; therefore, some interest has been focused on treating the pulmonary vascular impairment these diseases... - Interstitial lung disease in the patient who has connective tissue diseaseCharlie Strange
Division of Pulmonary and Critical Care Medicine, Medical University of South Carolina, 96 Jonathan Lucas Street, 812 CSB, Charleston, SC 29425, USA
Clin Chest Med 25:549-59, vii. 2004..Additionally, the challenge of finding the patient who has occult connective tissue disease in an interstitial lung disease clinic is discussed... - Pleural complications in the intensive care unitC Strange
Medical Intensive Care Unit, Medical University of South Carolina, Charleston, USA
Clin Chest Med 20:317-27. 1999..Correct diagnosis and therapy of pleural effusions will assist in improving pulmonary physiology and outcome in the ICU patient... - Hemodynamic effects of epoprostenol in patients with systemic sclerosis and pulmonary hypertensionC Strange
Division of Pulmonary and Critical Care Medicine, Allergy and Clinical Immunology, Medical University of South Carolina, Charleston, USA
Chest 118:1077-82. 2000..To determine the cause of pulmonary hypertension (PH) in systemic sclerosis (SSc) patients since PH can occur because of pulmonary arteriopathy, pulmonary parenchymal destruction, and left ventricular cardiac dysfunction... - Bullous sarcoidosis: a report of three casesM A Judson
Division of Pulmonary and Critical Care Medicine, Medical University of South Carolina, Charleston 29425, USA
Chest 114:1474-8. 1998..Additional clues are the presence of mediastinal adenopathy on a chest radiograph or a CT scan and a history consistent with extrapulmonary sarcoidosis... - Does genetic testing result in behavioral health change? Changes in smoking behavior following testing for alpha-1 antitrypsin deficiencyMatthew J Carpenter
Medical University of South Carolina, Hollings Cancer Center, Department of Psychiatry and Behavioral Sciences, Charleston, SC 29425, USA
Ann Behav Med 33:22-8. 2007..As genetic testing for health risk becomes increasingly available, it becomes important to study the prospective impact of testing on modifiable health behavior... - A 56-year-old woman with arm pain, dyspnea, and an elevated diaphragmMeena Kalluri
Medical University of South Carolina, Division of Pulmonary and Critical Care, 96 Jonathan Lucas St, 812CSB, Charleston, SC 29425, USA
Chest 133:296-9. 2008 - Long-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease. A meta-analysisKristin B Highland
Division of Pulmonary, Critical Care, Allergy and Clinical Immunology, Medical University of South Carolina, 96 Jonathan Lucas Street, 812 CSB, Box 250623, Charleston, South Carolina 29425, USA
Ann Intern Med 138:969-73. 2003..There is no consensus on the effectiveness of inhaled corticosteroids for the treatment of chronic obstructive pulmonary disease (COPD)... 
Pulmonary manifestations of systemic lupus erythematosusDiane L Kamen
Medical University of South Carolina, Charleston, SC 29425, USA
Clin Chest Med 31:479-88. 2010..Finding the true prevalence of lung involvement with SLE is complicated by the high rates of pulmonary infections. This article reviews the diverse clinical symptoms and immunologic pulmonary manifestations of SLE...- Treatment of pulmonary arterial hypertension: a preliminary decision analysisKristin B Highland
Division of Pulmonary, Critical Care, Allergy, and Clinical Immunology, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 812 CSB, Charleston, SC 29425, USA
Chest 124:2087-92. 2003..Clinicians must chose between very different therapies without the availability of comparison studies. We constructed a "virtual" clinical trial to help inform these treatment choices... - Pneumothorax in cystic fibrosisPatrick A Flume
Department of Medicine, Medical University of South Carolina, 96 Jonathan Lucas St, 812 CSB, Charleston, SC 29425, USA
Chest 128:720-8. 2005..An understanding of the pathophysiology of this complication and its consequences is important for the management of patients with CF... - Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung diseaseDonald P Tashkin
Department of Medicine, David Geffen School of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90095 1690, USA
Am J Respir Crit Care Med 176:1026-34. 2007..Although treatment-related benefits in pulmonary function, skin scores, and patient-centered outcomes were demonstrated after 1 year of therapy, the duration of benefit beyond 1 year was unclear... - Radiation therapy for palliation of Eisenmenger's syndrome-associated painful splenomegalyJonathan I Osorio
School of Medicine Medical University of South Carolina, Charleston, SC 29425, USA
Radiat Med 26:84-7. 2008..0-2.5 Gy per fraction to a total dose approaching 40 Gy for adequate duration of response when treating cardiogenic-associated painful splenomegaly in patients for whom surgical splenectomy cannot be performed... - Genetic testing for alpha1-antitrypsin deficiencyCharlie Strange
Division of Pulmonary and Critical Care Medicine, Medical University of South Carolina, 96 Jonathan Lucas Street, 812 CSB, Charleston, SC 29425, USA
Genet Med 6:204-10. 2004..The Alpha Coded Testing Study investigated the risks, benefits, and psychological impact of home genetic testing for alpha1-antitrypsin deficiency... - Evaluation of an intensive insulin protocol for septic patients in a medical intensive care unitStephanie B Clayton
Department of Pharmacy Services, Medical University of South Carolina, Charleston, SC, USA
Crit Care Med 34:2974-8. 2006.... - Management of spontaneous pneumothorax: an American College of Chest Physicians Delphi consensus statementM H Baumann
Division of Pulmonary and Critical Care Medicine, University of Mississippi Medical Center, Jackson, MS 39216 4505, USA
Chest 119:590-602. 2001..The guideline was designed to be relevant to physicians who make management decisions for the care of patients with pneumothorax... - Scleroderma lung disease: "if you don't know where you are going, any road will take you there"Charlie Strange
Am J Respir Crit Care Med 177:1178-9. 2008 - Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysisOliver Distler
University Hospital Zurich, Zurich, Switzerland
Arthritis Rheum 59:867-75. 2008..The aim of the present study was to establish an expert consensus regarding which outcome measures are most appropriate for clinical trials in PAH-SSc... - High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung diseaseJonathan G Goldin
David Geffen School of Medicine at UCLA, Department of Radiology, Los Angeles, CA 90095 1721, USA
Chest 134:358-67. 2008..The frequency, nature, and progression of interstitial lung disease seen on high-resolution CT (HRCT) scans in patients with diffuse SSc (dcSSc) compared with those with limited SSc (lcSSc) has not been well characterized... - alpha1-Antitrypsin augmentation therapy for PI*MZ heterozygotes: a cautionary noteRobert A Sandhaus
National Jewish Medical and Research Center, Denver, CO, USA
Chest 134:831-4. 2008..This commentary discusses the treatment of AAT deficiency and the concerns regarding treatment of PI*MZ individuals. We conclude that clinicians should avoid prescribing augmentation therapy for this heterozygote population... - Primary care diagnosis of alpha-1 antitrypsin deficiency: issues and opportunitiesJames K Stoller
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, USA
Cleve Clin J Med 74:869-74. 2007..The authors discuss impediments to diagnosis and drivers to making the diagnosis of alpha-1 antitrypsin deficiency, and they suggest several measures to enhance clinicians' recognition of the condition... - IL10 polymorphisms are associated with airflow obstruction in severe alpha1-antitrypsin deficiencyDawn L DeMeo
Brigham and Women s Hospital, Channing Laboratory, 181 Longwood Avenue, Boston, MA 02115, USA
Am J Respir Cell Mol Biol 38:114-20. 2008..Haplotype analysis of IL10 SNPs suggested the strongest association with IL10 promoter SNPs. IL10 is likely an important modifier gene for the development of COPD in individuals with severe AAT deficiency... - Factors associated with advanced liver disease in adults with alpha1-antitrypsin deficiencyChristopher L Bowlus
Division of Gastroenterology, University of California at Davis, UC Davis Medical Center, 4150 V Street, PSSB 3500, Sacramento, CA 95817, USA
Clin Gastroenterol Hepatol 3:390-6. 2005..Our study aim was to characterize the liver disease in AAT and identify factors associated with advanced liver disease... - Asthma and allergy in alpha-1 antitrypsin deficiencyEdward Eden
Department of Pulmonary and Critical Care Medicine, St Luke s Roosevelt Hospital, Columbia University, New York, NY, USA
Respir Med 100:1384-91. 2006..Those with AATD who are susceptible to asthma require allergy evaluation and aggressive anti-inflammatory strategies as part of their management... - Cyclophosphamide versus placebo in scleroderma lung diseaseDonald P Tashkin
University of California at Los Angeles, Los Angeles, USA
N Engl J Med 354:2655-66. 2006.... - Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung studyDinesh Khanna
University of Cincinnati, Cincinnati, Ohio 45267 0563, USA
Arthritis Rheum 56:1676-84. 2007..To assess the impact of cyclophosphamide (CYC) on the health-related quality of life (HRQOL) of patients with scleroderma after 12 months of treatment... - Multi-center study: the biochemical efficacy, safety and tolerability of a new alpha1-proteinase inhibitor, ZemairaJames M Stocks
The University of Texas Health Center at Tyler, 11937 US Hwy 271, Tyler, TX 75708-3154, USA
COPD 3:17-23. 2006..These results demonstrate that the new plasma derived alpha1-PI (Zemaira) is bioequivalent to the currently available product Prolastin, is well tolerated, and safe with respect to the risk of viral transmission... - Determinants of airflow obstruction in severe alpha-1-antitrypsin deficiencyDawn L DeMeo
Channing Laboratory, 181 Longwood Avenue, Boston, Massachusetts 02115, USA
Thorax 62:806-13. 2007..A study was undertaken to assess the impact of chronic bronchitis, pneumonia, asthma and sex on the development of COPD in individuals with severe AAT deficiency... - Delay in diagnosis of alpha1-antitrypsin deficiency: a continuing problemJames K Stoller
Department of Pulmonary, Allergy, and Critical Care Medicine, Cleveland Clinic Foundation, A 90, 9500 Euclid Ave, Cleveland, OH 44195, USA
Chest 128:1989-94. 2005..We also determined whether individuals living near medical centers with an expressed interest in AAT deficiency experienced shorter diagnostic delays than those living at a distance... - Treatment for secondary pulmonary hypertensionCharlie Strange
Chest 128:1897-8. 2005 - Mortality in individuals with severe deficiency of alpha1-antitrypsin: findings from the National Heart, Lung, and Blood Institute RegistryJames K Stoller
Department of Pulmonary, Allergy, and Critical Care Medicine, The Cleveland Clinic Foundation, 9500 Euclid Ave, A90, Cleveland, OH 44195, USA
Chest 127:1196-204. 2005..2 years)... - "The lion, the witch and the wardrobe": impact on sibs of individuals with AAT deficiencyJoanna H Fanos
Research Institute and Department of Pediatrics, California Pacific Medical Center, San Francisco, California 94115, USA
Am J Med Genet A 130:251-7. 2004..4) Awareness of liver disease from AAT deficiency should be increased... - Alpha-1 Foundation research registry: from the past to the futureCharlie Strange
J Pediatr Gastroenterol Nutr 34:1. 2002 - Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survivalRaymond L Benza
University of Alabama at Birmingham, 1900 University Blvd, Tinsley Harrison Towers, Room 328A, Birmingham, AL 35294, USA
Chest 134:775-82. 2008..Long-term efficacy evaluations are needed to guide therapeutic management. The purpose of this study is to present 1-year observational data with two endothelin antagonists, sitaxsentan and bosentan, in a prospective, open-label study...